67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

diseases per page:

Showing 1 to 10 of 221 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05373264 (ClinicalTrials.gov)	February 2023	28/4/2022	HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life	HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life	ADPKD	Drug: Hydrochlorothiazide 25 mg;Drug: Placebo	University Medical Center Groningen	NULL	Not yet recruiting	18 Years	80 Years	All	300	Phase 3	Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States
2	NCT04939935 (ClinicalTrials.gov)	November 2022	16/6/2021	Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease( ...	Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease( ...	Autosomal Dominant Polycystic Kidney Disease	Drug: Metformin XR;Other: Control	The University of Queensland	NULL	Not yet recruiting	18 Years	70 Years	All	1164	Phase 3	Australia
3	NCT05510115 (ClinicalTrials.gov)	October 17, 2022	11/8/2022	Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease	Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease	Polycystic Kidney, Autosomal Dominant	Drug: Empagliflozin;Drug: Placebo	University of Colorado, Denver	University of Maryland	Not yet recruiting	18 Years	50 Years	All	50	Phase 2	United States
4	NCT05521191 (ClinicalTrials.gov)	October 6, 2022	24/8/2022	A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease	A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Patients With Autosom ...	Autosomal Dominant Polycystic Kidney Disease;ADPKD;Polycystic Kidney, Autosomal Dominant	Drug: RGLS8429;Drug: Placebo	Regulus Therapeutics Inc.	NULL	Recruiting	18 Years	70 Years	All	36	Phase 1	United States
5	NCT05190744 (ClinicalTrials.gov)	September 1, 2022	29/12/2021	PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKDTreated With Tolvaptan, and Severely Pol ...	A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine O ...	Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Dia ...	Drug: PB	Mayo Clinic	Hopital du Sacre-Coeur de Montreal	Recruiting	18 Years	N/A	All	20	Phase 2	United States
6	NCT04782258 (ClinicalTrials.gov)	July 15, 2022	19/2/2021	A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Th ...	A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in In ...	Autosomal Recessive Polycystic Kidney (ARPKD)	Drug: Tolvaptan Suspension;Drug: Tolvaptan Tablets	Otsuka Pharmaceutical Development & Commercialization, Inc.	NULL	Recruiting	28 Days	18 Years	All	10	Phase 3	United States;Belgium;France;Germany;Italy;Poland;United Kingdom
7	NCT04786574 (ClinicalTrials.gov)	July 1, 2022	19/2/2021	A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days ...	A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in In ...	Autosomal Recessive Polycystic Kidney Disease (ARPKD)	Drug: Tolvaptan (OPC-41061)	Otsuka Pharmaceutical Development & Commercialization, Inc.	NULL	Recruiting	28 Days	12 Weeks	All	20	Phase 3	United States;Belgium;Germany;Italy;United Kingdom
8	NCT05478083 (ClinicalTrials.gov)	June 1, 2022	9/5/2022	A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease	A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease	Polycystic Liver Disease;Autosomal Dominant Polycystic Kidney	Drug: Leuprorelin	University Medical Center Groningen	Radboud University Medical Center	Recruiting	18 Years	45 Years	Female	36	Phase 2	Netherlands
9	NCT05401409 (ClinicalTrials.gov)	May 5, 2022	27/5/2022	Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease	Double-Blind, Randomised Placebo-Controlled Study to Determine the Effect of Beetroot Juice on Reduc ...	Autosomal Dominant Polycystic Kidney;Hypertension;Endothelial Dysfunction	Dietary Supplement: Beetroot juice;Dietary Supplement: Nitrate -depleted beetroot juice	Western Sydney Local Health District	Westmead Institute for Medical Research	Recruiting	18 Years	70 Years	All	60	N/A	Australia
10	ITMCTR2200005823	2022-04-15	2022-04-07	A multicenter cohort study of Tovastan combined with Shenfu Xiaozheng Decoction in the treatment of ...	A multicenter cohort study of Tovastan combined with Shenfu Xiaozheng Decoction in the treatment of ...	ADPKD	3:Tolvaptan+traditional Chinese medicine;1:Basic Western medicine treatment;4:traditional Chinese me ...	Hangzhou hospital of Traditional Chinese Medicine	NULL	Pending	18	70	Both	3:10;1:10;4:10;2:10;	Phase 1	China

First Previous1 2 3 4 5…23Next Last